New EU indication for Novartis's Lucentis
This article was originally published in Scrip
Executive Summary
Novartis's Lucentis (ranibizumab) has now received EU approval for a fourth indication: choroidal neovascularization (CNV) secondary to pathologic myopia (myopic CNV).
You may also be interested in...
Keeping Track: FDA Rejects Mealtime Insulin, Antihistamine; Misses Goal For Another Opioid
The latest drug development news and highlights from our FDA Performance Tracker.
The Shifting Sands Of Biopharma R&D
A year is a long time in biopharma. Pharmaprojects’ annual pipeline review finds changes in the therapeutic spread of drug candidates and a reordering of the top R&D companies, as Chinese firms made their presence felt all the more over the past 12 months.
Nine Pivotal Studies To Look Out For In 2024
While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are nine (plus a few extras) that have caught attention for one reason or another, e.g., for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.